[Skip to content]

European Parkinson's Disease Association
Search our Site

Research papers


Measurement and diagnosis research papers

  • Brain Volume 139 Issue 4 In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PETThe magnitude of the nigral signal loss was smaller than the decrease in striatal dopamine transporter signal measured by dopamine transporter single photon emission computed tomography. Study findings suggest a more severe loss of striatal nerve terminal function compared with neuronal cell bodies, in accordance with the post-mortem literature. 01 July 2016
  • Parkinsonism & Related Disorders Volume 28 How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort?Conclusions: TD versus PIGD subtype classification has substantial variability over first year in PD de novo cohort specifically for PIGD subtype. Dopaminergic therapy does not impact the change of the PD subtype. This instability has to be taken into consideration specifically when establishing correlations with the biomarkers and for long term prognostication. 01 July 2016
  • npj Parkinson's Disease Blood biomarker for Parkinson disease: peptoidsAuthors identified a peptoid, PD2, which binds significantly higher levels of IgG3 antibody in PD versus control subjects (P<0.0001) and is 68% accurate in identifying PD. 23 June 2016
  • JAMA Neurology Volume 70 Issue 7 Time Trends in the Incidence of Parkinson DiseaseThis study suggests that the incidence of parkinsonism and PD may have increased between 1976 and 2005, particularly in men 70 years and older. These trends may be associated with the dramatic changes in smoking behavior that took place in the second half of the 20th century or with other lifestyle or environmental changes. However, the trends could be spurious and need to be confirmed in other populations. 20 June 2016
  • Movement Disorders Volume 31 Issue 6 The NINDS Parkinson's disease biomarkers programConclusions: By making samples and data widely available, using stringent operating procedures based on existing standards, hypothesis testing for biomarker discovery, and providing a resource that complements existing programs, the Parkinson's Disease Biomarker Program will accelerate the pace of PD biomarker research. 15 June 2016
  • Movement Disorders Volume 31 Issue 6 The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohortThe study cohort provides a valuable resource for biomarker discovery and validation in PD. Clinical data and biospecimens, available through The Michael J. Fox Foundation for Parkinson's Research and the National Institute of Neurological Disorders and Stroke, can serve as a platform for discovering biomarkers in clinically typical PD and comparisons across PD's broad and heterogeneous spectrum. 15 June 2016
  • Movement Disorders Volume 31 Issue 6 Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's DiseaseConclusion: CSF biomarkers reflecting Lewy body pathology and neurodegeneration (α-synuclein), neuronal degeneration (tau, phosphorylated tau, and neurofilament light), and inflammation (YKL-40) increase significantly over 2 years in PD. CSF levels of α-synuclein and tau correlate and remain stable in the early symptomatic phase of PD but increase in the later phase. Authors hypothesize that CSF α-synuclein levels might increase as a result of more intense neurodegeneration in PD with long disease duration. 15 June 2016
  • Movement Disorders Volume 31 Issue 6 Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriersConclusion: The CSF protein profile differs in LRRK2-associated PD and idiopathic PD, suggesting that pathophysiological mechanisms different from IPD underlie LRRK2-associated PD. Cerebrospinal fluid biomarkers did not prove helpful in differentiating asymptomatic LRRK2 mutation carriers from noncarriers. 15 June 2016
  • Neurology Postural instability and gait are associated with severity and prognosis of Parkinson diseaseConclusions: In contrast to PIGD, which consistently was associated with greater severity of nondopaminergic symptoms, there was no evidence of a benign effect of tremor. Our findings do not support the use of the TD subtype as a prognostic trait in PD. The results showed that severity of PIGD is a useful indicator of severity and prognosis in PD by itself. 14 June 2016
  • Parkinsonism & Related Disorders Volume 27 Validation of the UPDRS section IV for detection of motor fluctuations in Parkinson's diseaseResults: Sixty two PD patients were enrolled in the study. According to the raters' evaluations, 39 (62.9%) were classified as having motor fluctuations, while according to the UPDRS-IV 47 (75.8%) presented a motor fluctuation giving a sensitivity of 87.2% (95%CI 72.6-95.7) and a specificity of 43.5% (95%CI 23.2-65.5). 01 June 2016
Page: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [+11]